Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates OKYO Bullish with a Setup Score of 0, net conviction 35, actionability 0. How the Setup Score works →
| Total Setup Score | 0 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 35 |
| Actionability | 0 (no mans land) |
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. Read full Trend Edge analysis →
| Current Price | $1.42 |
|---|---|
| Market Cap | $72.9M |
| Float | 27.9M |
| Shares Outstanding | 52.5M |
| vs. Analyst Target | +486.9% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $8.33 (3 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2021 | N/A | -$3.4M | -$13,086 | -$3.4M |
| 2022 | N/A | -$5.4M | -$2,423 | -$6.2M |
| 2023 | N/A | -$13.3M | -$3,797 | -$13.2M |
| 2024 | N/A | -$16.8M | -$3,866 | -$15.7M |
| 2025 | N/A | -$4.7M | -$2,563 | -$7.1M |
| 2026 | N/A | -$8.9M | N/A | -$8.5M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Dec 2024 | N/A | -$1,013 |
| Mar 2025 | N/A | -$2.0M |
| Jun 2025 | N/A | -$2.0M |
| Sep 2025 | N/A | -$2.6M |
| Insider Ownership | 31.1% |
|---|---|
| Institutional Ownership | 20.1% |
| Short Float | 0.2% |
| % of All Funds Holding | 0.22% |
| Number of Funds Holding | 19 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $1.48 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $1.66 | Medium-term trend |
| Weekly | 80-Week SMA | $1.91 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $1.67 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $1.61 | Near-term monthly trend |
| Monthly | 20-Month SMA | $1.86 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $1.64 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $2.00 | resistance | 1.80x | 7 months ago |
| $2.90 | resistance | 1.33x | 13 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.62% | -1.46% | 28.57% | 14.29% | -6.10% |
| 1 Day | 4.26% | 2.72% | 71.43% | 25.51% | -3.95% |
| 1 Week | -2.47% | -2.44% | 42.86% | 6.17% | -15.77% |
| 2 Weeks | 4.74% | -5.98% | 28.57% | 85.37% | -22.40% |
| 1 Month | -3.42% | -17.56% | 42.86% | 22.45% | -30.28% |
Next earnings: July 17, 2026
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.29% | 41.2% | 204 |
| Tuesday | -0.28% | 41.9% | 227 |
| Wednesday | 0.42% | 43.8% | 226 |
| Thursday | -0.01% | 40.9% | 220 |
| Friday | 0.72% | 52.3% | 222 |
Institutional holder breakdown coming soon.
Total institutional ownership: 20.1%
Total insider ownership: 31.1%
Founder-led management: Gary Jacob (Chief Development Officer & Director)
| Total Filings | 6 |
|---|---|
| Net Value | +$60,995.87 |
| Net Shares Change | 94,363 |
| % of Float | 0.3% |
| C-Suite Filings | 4 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| CERRONE GABRIELE M | +$67,625.75 | 1 | 1 buy | |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | +$28,000 | 1 | 1 buy |
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | +$23,085 | 1 | 1 buy |
| BRANCACCIO JOHN P | +$7,385 | 1 | 1 buy | |
| Patil Rajkumar V. | Chief Scientific Officer | +$5,010.87 | 1 | 1 buy |
| JACOB GARY S | CHIEF DEVELOPMENT OFFICER | +$4,900 | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-08-07 – 2026-08-07 | 6 | 6 | +$136,006.62 | 4 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-08-07 | Patil Rajkumar V. | Chief Scientific Officer | +$5,010.87 | Transaction at $1.49, now -4.7% |
| 2026-08-07 | Mantelli Flavio | CHIEF MEDICAL OFFICER | +$28,000 | Transaction at $1.40, now +1.4% |
| 2026-08-07 | Dempsey Robert John | CHIEF EXECUTIVE OFFICER | +$23,085 | Transaction at $1.54, now -7.7% |
| 2026-08-07 | JACOB GARY S | CHIEF DEVELOPMENT OFFICER | +$4,900 | Transaction at $1.40, now +1.4% |
| 2026-08-07 | BRANCACCIO JOHN P | +$7,385 | Transaction at $1.48, now -3.9% | |
| 2026-08-07 | CERRONE GABRIELE M | +$67,625.75 | Transaction at $1.42, now -0.3% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for OKYO Pharma Limited (OKYO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for OKYO on Trend Edge →